T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies

British Journal of Haematology

Volumn 157, Issue 5, 2012, Pages 580-585

  Auer, Rebecca L ^a   MacDougall, Finlay ^a   Oakervee, Heather E ^a   Taussig, David ^a   Davies, Jeff K ^a   Syndercombe Court, Denise ^a   Agrawal, Samir ^a   Cavenagh, Jamie D ^a   Lister, T Andrew ^a   Gribben, John G ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Fludarabine cyclophosphamide; Lymphoid malignancies; Reduced intensity allogeneic stem cell transplant

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FOLLICULAR LYMPHOMA; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RISK BENEFIT ANALYSIS; T CELL DEPLETION; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; CYCLOPHOSPHAMIDE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; RECURRENCE; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84860841088     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09106.x     Document Type: Article

References (23)

1. Armand, P., Gannamaneni, S., Kim, H.T., Cutler, C.S., Ho, V.T., Koreth, J., Alyea, E.P., LaCasce, A.S., Jacobsen, E.D., Fisher, D.C., Brown, J.R., Canellos, G.P., Freedman, A.S., Soiffer, R.J. & Antin, J.H. (2008) Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. Journal of Clinical Oncology, 26, 5767-5774.
2. Avivi, I., Montoto, S., Canals, C., Maertens, J., Al-Ali, H., Mufti, G.J., Finke, J., Schattenberg, A., Fanin, R., Cornelissen, J.J., Vernant, J.P., Russell, N., Beguin, Y., Thomson, K., Verdonck, L.F., Kobbe, G., Tilly, H., Socie, G. & Sureda, A. (2009) Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. British Journal of Haematology, 147, 719-728.
3. Blade, J., Rosinol, L., Cibeira, M.T., Rovira, M. & Carreras, E. (2010) Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood, 115, 3655-3663.
4. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
5. Corradini, P., Dodero, A., Farina, L., Fanin, R., Patriarca, F., Miceli, R., Matteucci, P., Bregni, M., Scime, R., Narni, F., Pogliani, E., Locasciulli, A., Milani, R., Carniti, C., Bacigalupo, A., Rambaldi, A., Bonifazi, F., Olivieri, A., Gianni, A.M. & Tarella, C. (2007) Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia, 21, 2316-2323.
6. Delgado, J., Canals, C., Attal, M., Thomson, K., Campos, A., Martino, R., Littlewood, T., Jackson, G., Milpied, N., Boogaerts, M., Hunter, A., Janssen, J.J., Montoto, S. & Sureda, A. (2011) The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma. Leukemia, 25, 551-555.
7. Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
8. Farina, L., Bruno, B., Patriarca, F., Spina, F., Sorasio, R., Morelli, M., Fanin, R., Boccadoro, M. & Corradini, P. (2009) The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia, 23, 1131-1138.
9. Ingram, W., Devereux, S., Das-Gupta, E.P., Russell, N.H., Haynes, A.P., Byrne, J.L., Shaw, B.E., McMillan, A., Gonzalez, J., Ho, A., Mufti, G.J. & Pagliuca, A. (2008) Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. British Journal of Haematology, 141, 235-243.
10. Khouri, I.F., McLaughlin, P., Saliba, R.M., Hosing, C., Korbling, M., Lee, M.S., Medeiros, L.J., Fayad, L., Samaniego, F., Alousi, A., Anderlini, P., Couriel, D., de Lima, M., Giralt, S., Neelapu, S.S., Ueno, N.T., Samuels, B.I., Hagemeister, F., Kwak, L.W. & Champlin, R.E. (2008) Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood, 111, 5530-5536.
11. Kohrt, H.E., Turnbull, B.B., Heydari, K., Shizuru, J.A., Laport, G.G., Miklos, D.B., Johnston, L.J., Arai, S., Weng, W.K., Hoppe, R.T., Lavori, P.W., Blume, K.G., Negrin, R.S., Strober, S. & Lowsky, R. (2009) TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood, 114, 1099-1109.
12. Kroger, N., Sayer, H.G., Schwerdtfeger, R., Kiehl, M., Nagler, A., Renges, H., Zabelina, T., Fehse, B., Ayuk, F., Wittkowsky, G., Schmitz, N. & Zander, A.R. (2002) Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood, 100, 3919-3924.
13. Lokhorst, H., Einsele, H., Vesole, D., Bruno, B., San Miguel, J., Perez-Simon, J.A., Kroger, N., Moreau, P., Gahrton, G., Gasparetto, C., Giralt, S. & Bensinger, W. (2010) International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. Journal of Clinical Oncology, 28, 4521-4530.
14. Morris, E., Thomson, K., Craddock, C., Mahendra, P., Milligan, D., Cook, G., Smith, G.M., Parker, A., Schey, S., Chopra, R., Hatton, C., Tighe, J., Hunter, A., Peggs, K., Linch, D., Goldstone, A. & Mackinnon, S. (2004) Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 104, 3865-3871.
15. Peggs, K.S., Mackinnon, S., Williams, C.D., D'Sa, S., Thuraisundaram, D., Kyriakou, C., Morris, E.C., Hale, G., Waldmann, H., Linch, D.C., Goldstone, A.H. & Yong, K. (2003) Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biology of Blood Marrow Transplantation, 9, 257-265.
16. Pinana, J.L., Martino, R., Gayoso, J., Sureda, A., de la Serna, J., Diez-Martin, J.L., Vazquez, L., Arranz, R., Tomas, J.F., Sampol, A., Solano, C., Delgado, J., Sierra, J. & Caballero, D. (2010) Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica, 95, 1176-1182.
17. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J. & Thomas, E.D. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplantation, 15, 825-828.
18. Ratanatharathorn, V., Logan, B., Wang, D., Horowitz, M., Uberti, J.P., Ringden, O., Gale, R.P., Khoury, H., Arora, M., Spellman, S., Cutler, C., Antin, J., Bornhauser, M., Hale, G., Verdonck, L., Cairo, M., Gupta, V. & Pavletic, S. (2009) Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. British Journal of Haematology, 145, 816-824.
19. Rezvani, A.R., Storer, B., Maris, M., Sorror, M.L., Agura, E., Maziarz, R.T., Wade, J.C., Chauncey, T., Forman, S.J., Lange, T., Shizuru, J., Langston, A., Pulsipher, M.A., Sandmaier, B.M., Storb, R. & Maloney, D.G. (2008) Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology, 26, 211-217.
20. Soiffer, R.J. (ed.) (2008) Haematopoietic Stem Cell Transplantation. Humana Press, Totowa, NJ.
21. Taussig, D.C., Davies, A.J., Cavenagh, J.D., Oakervee, H., Syndercombe-Court, D., Kelsey, S., Amess, J.A., Rohatiner, A.Z., Lister, T.A. & Barnett, M.J. (2003) Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. Journal of Clinical Oncology, 21, 3060-3065.
22. Thomson, K.J., Morris, E.C., Bloor, A., Cook, G., Milligan, D., Parker, A., Clark, F., Yung, L., Linch, D.C., Chakraverty, R., Peggs, K.S. & Mackinnon, S. (2009) Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology, 27, 426-432.
23. Thomson, K.J., Morris, E.C., Milligan, D., Parker, A.N., Hunter, A.E., Cook, G., Bloor, A.J., Clark, F., Kazmi, M., Linch, D.C., Chakraverty, R., Peggs, K.S. & Mackinnon, S. (2010) T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. Journal of Clinical Oncology, 28, 3695-3700.